Research showed that circulating free DNA, circulating tumor cell, circulating tumor DNA and microRNA in blood or cerebrospinal fluid were used for GBM early diagnosis, early tumor progression detection, monitoring of tumor treatment response, personalized treatment identification, such as EGFR, TGF-β, IDH, miR-21and so on. This evidence concerns the gene EGFR and neoplasm.